Growth Metrics

Zevra Therapeutics (ZVRA) R&D In Process (2022)

Zevra Therapeutics (ZVRA) has disclosed R&D In Process for 1 consecutive years, with $17.7 million as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, R&D In Process changed N/A year-over-year to $17.7 million, compared with a TTM value of $17.7 million through Sep 2022, changed N/A, and an annual FY2022 reading of $17.7 million, changed N/A over the prior year.
  • R&D In Process was $17.7 million for Q2 2022 at Zevra Therapeutics.
  • Across five years, R&D In Process topped out at $17.7 million in Q2 2022 and bottomed at $17.7 million in Q2 2022.